PROCEPT BioRobotics Corporation
PRCT is a BUY because a 3.06x TTM P/S valuation and a stock 50.6% below its 52-week high underprice a 41.1% FY2025 revenue grower, while appropriately leaving conviction at Medium until profitability and earnings accuracy improve.
PRCT offers a favorable setup because the market is pricing a fast-growing robotic-urology company as though the commercial ramp has already failed. At $18.82, the equity trades at 3.06x TTM sales, below the supplied 6.0x peer average, while the share price is 50.6% below the 52-week high and 81.1% below the five-year high. That discount is not simply an abstract valuation statistic. It gives investors exposure to a business that is still adding systems and procedure capacity without paying a premium multiple for success.
The investment case depends first on commercial persistence. HYDROS was already driving roughly 80% of Q3 2024 system placements, while the company had built a U.S. installed base of 445 systems. Each placement can produce a longer-lived stream of procedure demand and handpiece revenue. The prior-quarter disclosure of a roughly $432K blended system ASP shows the economic relevance of capital placement, while the expected 9,950 Q4 2024 handpieces illustrates the consumable layer. The market needs evidence that this mix can keep expanding, not merely another quarter of hardware sales.
The second dependency is cost conversion. PRCT is not investable as a near-term earnings compounder at present. Its LTM net margin was -32.5%, and the February 2026 EPS shortfall of 65.6% versus consensus showed how vulnerable expectations are when losses remain large. Yet FY2025 operating margin improved by 430 basis points. If revenue continues to scale while sales, training, manufacturing, and support costs grow more slowly, the equity can move from being valued on hope to being valued on credible future earnings power.
The third dependency is evidence and platform relevance. The WATER IV prostate-cancer program, designed for up to 280 patients across up to 50 centers, is strategically important because expanded clinical validation could widen the platform's use case. AI can improve robotic imaging, planning, and workflow, but PRCT has not disclosed an AI-derived revenue or regulatory advantage. That limits conviction, but it also means the valuation does not appear to price a speculative AI narrative. Medium conviction reflects a discounted entry point and meaningful operating upside, offset by unresolved cash burn, opaque current guidance, and a recent miss streak.
HYDROS placements and procedure pull-through accelerate while operating leverage closes the gap from -33.9% LTM operating margin toward breakeven.
Sustained commercial growth and continued loss-margin improvement support the quantitative sales-quality-blend target.
Revenue decelerates and losses remain near the -33.9% LTM operating margin, leaving PRCT valued closer to a distressed growth-device asset.
Quant call aligns with analyst consensus (Strong Buy: 3 buy / 3 hold / 0 sell).
Never, ever invest in the present.
Forward P/E cannot yet be calculated because PRCT remains loss-making and no forward EPS estimate or current management guide was supplied; the trailing P/E is also N/A, so the relevant valuation anchor is 3.06x TTM P/S, not earnings. HYDROS and its procedure consumables provide a credible moat today through specialized robotic hardware, clinical workflow, and installed-base utilization, but that moat is less certain over 3-5 years if larger surgical-robotics platforms narrow the technology gap. AI is an enabling tool for imaging, planning, workflow and outcomes data, not a disclosed PRCT profit pool or durable standalone advantage today; FDA requirements and clinical evidence, including the planned WATER IV PCa trial of up to 280 patients, will determine whether software and platform extensions expand the addressable market.
- FY2025 revenue grew 41.1%, a growth rate that supports a recovery from the current 3.06x TTM P/S valuation.
- The shares trade at $18.82, or 50.6% below the $38.11 52-week high, versus a $32.50 base-case value.
- FY2025 operating margin improved 430 bps to -38.7% from -43.0%, establishing operating leverage as the central earnings variable.
- FY2025 revenue of $0.3B grew 41.1% YoY, far above a mature-device growth profile.
- The 3.06x TTM P/S ratio is roughly half the supplied 6.0x peer average, despite PRCT's 41.1% FY2025 revenue growth.
- HYDROS commercialization had reached 445 U.S. installed systems by Q3 2024, up 64% YoY, creating a base for recurring handpiece procedures.
- Liquidity is substantial relative to obligations, with a 6.55 current ratio as of June 30, 2026 and debt/equity of 0.23.
- LTM operating margin was still -33.9% through June 30, 2026, so the company needs a large gross-profit conversion before a conventional earnings valuation is possible.
- PRCT missed EPS estimates in all three reported 2026 quarters, including a 65.6% miss on February 25, weakening confidence in near-term forecasting.
- LTM free cash flow was -$0.1B through June 30, 2026, leaving growth dependent on balance-sheet capacity rather than internally generated cash.
- Short interest is 13.60% of float, or 7.43M shares and 4.8 days-to-cover, which signals meaningful skepticism even if it can amplify a positive result.
| Metric | Value | Context |
|---|---|---|
| Share price | $18.82 | Current price, 50.6% below the $38.11 52-week high |
| Market capitalization | $1.0B | Current equity value |
| Revenue | $0.3B FY2025 | 41.1% YoY growth |
| EPS | -$1.72 FY2025 | -17.0% YoY |
| Operating margin | -38.7% FY2025 | Improved from -43.0% in prior FY |
| Operating margin | -33.9% LTM to 2026-06-30 | Still materially loss-making |
| Free cash flow | -$0.1B LTM to 2026-06-30 | Cash burn remains a valuation constraint |
| P/S | 3.06x TTM | Versus 6.0x peer average |
| Current ratio | 6.55x as of 2026-06-30 | Strong near-term liquidity coverage |
| Total debt | $0.1B as of 2026-06-30 | Debt/equity of 0.23 |
| Short interest | 13.60% of float | 7.43M shares, 4.8 days-to-cover |
| Quantitative price target | $32.50 | 72.7% upside, Medium confidence, sales-quality blend |
The primary risk is that revenue growth fails to cover a -33.9% LTM operating margin and -$0.1B LTM free cash flow deficit, extending the path to self-funded growth.
November 4, 2026 earnings, particularly whether PRCT reverses the three-quarter EPS-miss streak and provides an updated profitability framework.
Institutional ownership is concentrated, with the top three institutions holding 90.4% and insiders holding only 3.4%. Short interest of 13.60%, equal to 7.43M shares and 4.8 days-to-cover, creates both informed skepticism and potential upside torque on a strong earnings result. Options gamma is reported as positive within 45 days to expiry, but zero-gamma and call/put-wall values were not supplied, so no precise dealer-level price support or resistance can be inferred.
No current geographic revenue split was supplied. Q3 2024 international revenue was $6.2M, with the U.K. cited as a lead market, but that is stale and should not be treated as the current mix.
No current revenue split was supplied. In Q3 2024, PRCT sold 45 systems at roughly $432K blended ASP and expected approximately 9,950 handpieces in Q4, showing the capital-placement and consumables model.
Analysis unavailable
Management's Q3 2024 call set ambitious targets: FY2024 revenue of $222.5M-$223.0M, approximately 186 system sales, FY2024 gross margin of about 61%, and an adjusted EBITDA loss near $60M. The provided dataset does not include actual FY2024 revenue, system shipments, gross margin, or EBITDA, so it cannot verify whether those explicit commitments were met. What is observable is mixed: FY2025 revenue reached $0.3B and grew 41.1%, while FY2025 operating margin improved to -38.7% from -43.0%; however, reported EPS shifted from three beats in 2025, ranging from +7.3% to +14.6%, to three consecutive misses in 2026, ranging from -1.8% to -65.6%. Strategy remains centered on HYDROS-led system adoption and procedure pull-through, but credibility is presently moderate rather than high until current guidance and the earnings-miss pattern improve.
PRCT's protection comes from the AQUABEAM/HYDROS robotic workflow, urologist training, installed systems, and recurring procedure consumables. HYDROS had energized placements, with approximately 80% of Q3 2024 system sales coming from the platform, and the U.S. installed base was 445 systems at that point. The moat is real but still developing: a $1.0B market-cap company must keep proving clinical outcomes and utilization before its ecosystem can be considered durable against better-capitalized robotic competitors.
PRCT is funding expansion rather than returning capital. The deep-dive data show $0.0B of buybacks, dividends, and capex, while the financial dataset reports -$0.1B LTM free cash flow through June 30, 2026; the separate deep-dive cash-flow field reports positive $0.1B FCF, an inconsistency that prevents crediting the company with established cash generation. With total debt of $0.1B and a 6.55 current ratio, conserving liquidity for commercial execution is more disciplined than initiating shareholder returns.
PRCT is a BUY at Medium conviction for the next 6-12 months. The valuation, share-price reset, and still-strong revenue growth create a much better entry point than existed near prior highs. The call is conditional on evidence that LTM losses narrow and that the November 4 update restores earnings credibility. A sustained failure to improve from the -33.9% LTM operating margin, or another material earnings miss without a credible revised path, would move the rating to HOLD or SELL.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. PRCT rates a BUY, Medium conviction. The market value is only $1.0B despite FY2025 revenue growth of 41.1%, and the stock has already absorbed a severe derating to $18.82, creating asymmetric upside to the $32.50 base case. This is not a clean profitability story: LTM operating margin remains -33.9%, and the November 4 release must show that commercial growth can convert into lower losses.
Investment Thesis
PRCT offers a favorable setup because the market is pricing a fast-growing robotic-urology company as though the commercial ramp has already failed. At $18.82, the equity trades at 3.06x TTM sales, below the supplied 6.0x peer average, while the share price is 50.6% below the 52-week high and 81.1% below the five-year high. That discount is not simply an abstract valuation statistic. It gives investors exposure to a business that is still adding systems and procedure capacity without paying a premium multiple for success.
The investment case depends first on commercial persistence. HYDROS was already driving roughly 80% of Q3 2024 system placements, while the company had built a U.S. installed base of 445 systems. Each placement can produce a longer-lived stream of procedure demand and handpiece revenue. The prior-quarter disclosure of a roughly $432K blended system ASP shows the economic relevance of capital placement, while the expected 9,950 Q4 2024 handpieces illustrates the consumable layer. The market needs evidence that this mix can keep expanding, not merely another quarter of hardware sales.
The second dependency is cost conversion. PRCT is not investable as a near-term earnings compounder at present. Its LTM net margin was -32.5%, and the February 2026 EPS shortfall of 65.6% versus consensus showed how vulnerable expectations are when losses remain large. Yet FY2025 operating margin improved by 430 basis points. If revenue continues to scale while sales, training, manufacturing, and support costs grow more slowly, the equity can move from being valued on hope to being valued on credible future earnings power.
The third dependency is evidence and platform relevance. The WATER IV prostate-cancer program, designed for up to 280 patients across up to 50 centers, is strategically important because expanded clinical validation could widen the platform's use case. AI can improve robotic imaging, planning, and workflow, but PRCT has not disclosed an AI-derived revenue or regulatory advantage. That limits conviction, but it also means the valuation does not appear to price a speculative AI narrative. Medium conviction reflects a discounted entry point and meaningful operating upside, offset by unresolved cash burn, opaque current guidance, and a recent miss streak.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Share price | $18.82 | Current price, 50.6% below the $38.11 52-week high |
| Market capitalization | $1.0B | Current equity value |
| Revenue | $0.3B FY2025 | 41.1% YoY growth |
| EPS | -$1.72 FY2025 | -17.0% YoY |
| Operating margin | -38.7% FY2025 | Improved from -43.0% in prior FY |
| Operating margin | -33.9% LTM to 2026-06-30 | Still materially loss-making |
| Free cash flow | -$0.1B LTM to 2026-06-30 | Cash burn remains a valuation constraint |
| P/S | 3.06x TTM | Versus 6.0x peer average |
| Current ratio | 6.55x as of 2026-06-30 | Strong near-term liquidity coverage |
| Total debt | $0.1B as of 2026-06-30 | Debt/equity of 0.23 |
| Short interest | 13.60% of float | 7.43M shares, 4.8 days-to-cover |
| Quantitative price target | $32.50 | 72.7% upside, Medium confidence, sales-quality blend |
Financial Strength
PRCT has enough balance-sheet flexibility to continue investing, with a 6.55 current ratio as of June 30, 2026 and only $0.1B of total debt, but it has not established self-funding economics. The central financial question is the speed at which gross profit from a growing installed base absorbs commercial and operating costs. The FY2025 margin improvement is encouraging, but -$0.1B LTM free cash flow means liquidity is a cushion, not proof of financial maturity.
Competitive Position
PRCT's protection comes from the AQUABEAM/HYDROS robotic workflow, urologist training, installed systems, and recurring procedure consumables. HYDROS had energized placements, with approximately 80% of Q3 2024 system sales coming from the platform, and the U.S. installed base was 445 systems at that point. The moat is real but still developing: a $1.0B market-cap company must keep proving clinical outcomes and utilization before its ecosystem can be considered durable against better-capitalized robotic competitors.
Management & Guidance
No current management revenue, system-sales, margin, or cash-flow guidance was supplied from the 2026 Q2 call, so the next earnings release needs to refresh the underwriting case. The last detailed benchmark is stale: management raised FY2024 revenue guidance to $222.5M-$223.0M, gross-margin guidance to approximately 61%, and projected about 186 system placements. Given the three 2026 EPS misses, investors should require quantified current targets and a clear explanation of the path from growth to lower cash burn rather than rely on the 2024 framework.
Segment Analysis
- Geographic revenue (Not disclosed in provided data): No current geographic revenue split was supplied. Q3 2024 international revenue was $6.2M, with the U.K. cited as a lead market, but that is stale and should not be treated as the current mix.
- Robotic systems and recurring handpieces (Not disclosed in provided data): No current revenue split was supplied. In Q3 2024, PRCT sold 45 systems at roughly $432K blended ASP and expected approximately 9,950 handpieces in Q4, showing the capital-placement and consumables model.
Capital Allocation
PRCT is funding expansion rather than returning capital. The deep-dive data show $0.0B of buybacks, dividends, and capex, while the financial dataset reports -$0.1B LTM free cash flow through June 30, 2026; the separate deep-dive cash-flow field reports positive $0.1B FCF, an inconsistency that prevents crediting the company with established cash generation. With total debt of $0.1B and a 6.55 current ratio, conserving liquidity for commercial execution is more disciplined than initiating shareholder returns.
Management Execution & Track Record
Management's Q3 2024 call set ambitious targets: FY2024 revenue of $222.5M-$223.0M, approximately 186 system sales, FY2024 gross margin of about 61%, and an adjusted EBITDA loss near $60M. The provided dataset does not include actual FY2024 revenue, system shipments, gross margin, or EBITDA, so it cannot verify whether those explicit commitments were met. What is observable is mixed: FY2025 revenue reached $0.3B and grew 41.1%, while FY2025 operating margin improved to -38.7% from -43.0%; however, reported EPS shifted from three beats in 2025, ranging from +7.3% to +14.6%, to three consecutive misses in 2026, ranging from -1.8% to -65.6%. Strategy remains centered on HYDROS-led system adoption and procedure pull-through, but credibility is presently moderate rather than high until current guidance and the earnings-miss pattern improve.
Positioning & Flows
Institutional ownership is concentrated, with the top three institutions holding 90.4% and insiders holding only 3.4%. Short interest of 13.60%, equal to 7.43M shares and 4.8 days-to-cover, creates both informed skepticism and potential upside torque on a strong earnings result. Options gamma is reported as positive within 45 days to expiry, but zero-gamma and call/put-wall values were not supplied, so no precise dealer-level price support or resistance can be inferred.
Bull Case
- FY2025 revenue of $0.3B grew 41.1% YoY, far above a mature-device growth profile.
- The 3.06x TTM P/S ratio is roughly half the supplied 6.0x peer average, despite PRCT's 41.1% FY2025 revenue growth.
- HYDROS commercialization had reached 445 U.S. installed systems by Q3 2024, up 64% YoY, creating a base for recurring handpiece procedures.
- Liquidity is substantial relative to obligations, with a 6.55 current ratio as of June 30, 2026 and debt/equity of 0.23.
Bear Case
- LTM operating margin was still -33.9% through June 30, 2026, so the company needs a large gross-profit conversion before a conventional earnings valuation is possible.
- PRCT missed EPS estimates in all three reported 2026 quarters, including a 65.6% miss on February 25, weakening confidence in near-term forecasting.
- LTM free cash flow was -$0.1B through June 30, 2026, leaving growth dependent on balance-sheet capacity rather than internally generated cash.
- Short interest is 13.60% of float, or 7.43M shares and 4.8 days-to-cover, which signals meaningful skepticism even if it can amplify a positive result.
Valuation & Price Target
Engine price target $32.5 (+72.7% vs current), Medium confidence.
- P/S Multiple: $37.44 (45% weight)
- Quality-adjusted: $19.27 (20% weight)
- DCF: $45.23 (3% weight)
The BUY rating agrees with the quantitative baseline because the engine's $32.50 target offers 72.7% upside from $18.82 and PRCT trades at 3.06x TTM P/S versus a supplied 6.0x peer average. Medium rather than High conviction is warranted: the method range is exceptionally wide, from $19.27 quality-adjusted value to $45.23 DCF value, LTM free cash flow is -$0.1B, and the company has posted three straight 2026 EPS misses. Sell-side consensus is Strong Buy from 3 buys and 3 holds, but only six firms cover the name and that consensus is low-signal context, not the basis for the call.
Risk Assessment
Risk score 47/100 (Moderate). The primary risk is that revenue growth fails to cover a -33.9% LTM operating margin and -$0.1B LTM free cash flow deficit, extending the path to self-funded growth.
The Bottom Line
PRCT is a BUY at Medium conviction for the next 6-12 months. The valuation, share-price reset, and still-strong revenue growth create a much better entry point than existed near prior highs. The call is conditional on evidence that LTM losses narrow and that the November 4 update restores earnings credibility. A sustained failure to improve from the -33.9% LTM operating margin, or another material earnings miss without a credible revised path, would move the rating to HOLD or SELL.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr